title: Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma.
abstract: OBJECTIVE
  To evaluate adherence to oral montelukast and inhaled fluticasone in children with persistent asthma and to determine if age, monotherapy, and duration of therapy affect adherence.
  
  
  METHODS
  Retrospective analysis.
  
  
  METHODS
  Pediatric pulmonary clinic.
  
  
  METHODS
  One hundred seventy-one children with asthma who required continuous treatment with a controller agent year-round and in whom montelukast and/or fluticasone had been prescribed for at least 90 days.
  
  
  METHODS
  Montelukast monotherapy had been prescribed for 54 patients, fluticasone monotherapy for 48 patients, and combination therapy for 69 patients.
  
  
  RESULTS
  Prescription refill histories were obtained from pharmacies identified by the parents or from Medicaid pharmacy reimbursement records. The maximum possible adherence was calculated as [(no. of doses refilled)/(no. of doses prescribed)] x 100, for a mean observation period of 203 days (range 84-365 days) for montelukast and 314 days (range 97-365 days) for fluticasone. Median adherence rates were 59% (95% confidence interval [CI] 48-65%) for montelukast and 44% (90% CI 35-50%) for fluticasone. Adherence did not significantly correlate with age, length of observation period, or whether the patient was receiving monotherapy or combination therapy. The odds ratio for very poor adherence (< 50%) was 2.0 (95% CI 1.3-3.2) for fluticasone relative to montelukast.
  
  
  CONCLUSIONS
  Adherence to both drugs was suboptimal. However, these data indicate that our patients were likely to take montelukast more consistently than fluticasone. Whether this translates into better asthma control requires further study.
authors.affiliation: Department of Pediatrics, University of Florida, Gainesville, USA. shermjm@peds.ufl.edu
authors.forename: J
authors.initials: J
authors.lastname: Sherman
authors.forename: P
authors.initials: P
authors.lastname: Patel
authors.forename: A
authors.initials: A
authors.lastname: Hutson
authors.forename: S
authors.initials: S
authors.lastname: Chesrown
authors.forename: L
authors.initials: L
authors.lastname: Hendeles
mesh_terms: D000085:Acetates / Q000008:administration & dosage*; D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003521:Cyclopropanes; D000068298:Fluticasone; D006801:Humans; D007223:Infant; D010349:Patient Compliance; D011804:Quinolines / Q000008:administration & dosage*; D012189:Retrospective Studies; D013440:Sulfides
chemical_list: D000085:Acetates; D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D000068298:Fluticasone; C093875:montelukast